Literature DB >> 10890744

A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial.

P Walsh1, R Gonzalez, S Dow, R Elmslie, T Potter, L M Glode, A E Baron, C Balmer, K Easterday, J Allen, P Rosse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10890744     DOI： 10.1089/10430340050032447

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  3 in total

1.  Myth, menace or medical blessing? The clinical potential and the problems of genetic vaccines.

Authors:  W W Leitner
Journal:  EMBO Rep       Date:  2001-03       Impact factor: 8.807

Review 2.  Canine Cancer: Strategies in Experimental Therapeutics.

Authors:  Douglas H Thamm
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

3.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.